These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 30053382

  • 1. MAFG is a potential therapeutic target to restore chemosensitivity in cisplatin-resistant cancer cells by increasing reactive oxygen species.
    Vera-Puente O, Rodriguez-Antolin C, Salgado-Figueroa A, Michalska P, Pernia O, Reid BM, Rosas R, Garcia-Guede A, SacristÁn S, Jimenez J, Esteban-Rodriguez I, Martin ME, Sellers TA, León R, Gonzalez VM, De Castro J, Ibanez de Caceres I.
    Transl Res; 2018 Oct; 200():1-17. PubMed ID: 30053382
    [Abstract] [Full Text] [Related]

  • 2. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through MAFG Overexpression in Cancer Cells.
    Vera O, Jimenez J, Pernia O, Rodriguez-Antolin C, Rodriguez C, Sanchez Cabo F, Soto J, Rosas R, Lopez-Magallon S, Esteban Rodriguez I, Dopazo A, Rojo F, Belda C, Alvarez R, Valentin J, Benitez J, Perona R, De Castro J, Ibanez de Caceres I.
    Theranostics; 2017 Oct; 7(17):4118-4134. PubMed ID: 29158814
    [Abstract] [Full Text] [Related]

  • 3. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance.
    Feng J, Wen T, Li Z, Feng L, Zhou L, Yang Z, Xu L, Shi S, Hou K, Shen J, Han X, Teng Y.
    Aging (Albany NY); 2020 Oct 24; 12(20):20658-20683. PubMed ID: 33098638
    [Abstract] [Full Text] [Related]

  • 4. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
    Tung MC, Lin PL, Cheng YW, Wu DW, Yeh SD, Chen CY, Lee H.
    Oncotarget; 2016 May 31; 7(22):32362-74. PubMed ID: 27083050
    [Abstract] [Full Text] [Related]

  • 5. LncRNA MAFG-AS1 facilitates the migration and invasion of NSCLC cell via sponging miR-339-5p from MMP15.
    Jia YC, Wang JY, Liu YY, Li B, Guo H, Zang AM.
    Cell Biol Int; 2019 Apr 31; 43(4):384-393. PubMed ID: 30599080
    [Abstract] [Full Text] [Related]

  • 6. miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
    Zhang H, Hu B, Wang Z, Zhang F, Wei H, Li L.
    Cancer Chemother Pharmacol; 2017 Nov 31; 80(5):973-984. PubMed ID: 28956120
    [Abstract] [Full Text] [Related]

  • 7. Epigenetic silencing of miR-493 increases the resistance to cisplatin in lung cancer by targeting tongue cancer resistance-related protein 1(TCRP1).
    Gu Y, Zhang Z, Yin J, Ye J, Song Y, Liu H, Xiong Y, Lu M, Zheng G, He Z.
    J Exp Clin Cancer Res; 2017 Aug 31; 36(1):114. PubMed ID: 28859669
    [Abstract] [Full Text] [Related]

  • 8. Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma.
    Fang M, Hutchinson L, Deng A, Green MR.
    Proc Natl Acad Sci U S A; 2016 Feb 02; 113(5):1250-5. PubMed ID: 26787892
    [Abstract] [Full Text] [Related]

  • 9. miR-128 Is Implicated in Stress Responses by Targeting MAFG in Skeletal Muscle Cells.
    Caggiano R, Cattaneo F, Moltedo O, Esposito G, Perrino C, Trimarco B, Ammendola R, Faraonio R.
    Oxid Med Cell Longev; 2017 Feb 02; 2017():9308310. PubMed ID: 29138682
    [Abstract] [Full Text] [Related]

  • 10. MAFG-AS1/MAFG positive feedback loop contributes to cisplatin resistance in bladder urothelial carcinoma through antagonistic ferroptosis.
    Xiang L, Zeng Q, Liu J, Xiao M, He D, Zhang Q, Xie D, Deng M, Zhu Y, Liu Y, Bo H, Liu X, Zhou M, Xiong W, Zhou Y, Zhou J, Li X, Cao K.
    Sci Bull (Beijing); 2021 Sep 15; 66(17):1773-1788. PubMed ID: 36654385
    [Abstract] [Full Text] [Related]

  • 11. miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma.
    Bar J, Gorn-Hondermann I, Moretto P, Perkins TJ, Niknejad N, Stewart DJ, Goss GD, Dimitroulakos J.
    Clin Lung Cancer; 2015 Nov 15; 16(6):e121-9. PubMed ID: 25703099
    [Abstract] [Full Text] [Related]

  • 12. MafG controls the hypoxic response of cells by accumulating HIF-1alpha in the nuclei.
    Ueda K, Xu J, Morimoto H, Kawabe A, Imaoka S.
    FEBS Lett; 2008 Jul 09; 582(16):2357-64. PubMed ID: 18538669
    [Abstract] [Full Text] [Related]

  • 13. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer.
    Zhao J, Fu W, Liao H, Dai L, Jiang Z, Pan Y, Huang H, Mo Y, Li S, Yang G, Yin J.
    BMC Cancer; 2015 Oct 19; 15():731. PubMed ID: 26482648
    [Abstract] [Full Text] [Related]

  • 14. SNHG14 silencing suppresses the progression and promotes cisplatin sensitivity in non-small cell lung cancer.
    Jiao P, Hou J, Yao M, Wu J, Ren G.
    Biomed Pharmacother; 2019 Sep 19; 117():109164. PubMed ID: 31252267
    [Abstract] [Full Text] [Related]

  • 15. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W, Ping W, Tian Y, Zou W, Liu J, Zu Y.
    Cell Physiol Biochem; 2018 Sep 19; 51(5):2160-2171. PubMed ID: 30522099
    [Abstract] [Full Text] [Related]

  • 16. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
    Nogales V, Reinhold WC, Varma S, Martinez-Cardus A, Moutinho C, Moran S, Heyn H, Sebio A, Barnadas A, Pommier Y, Esteller M.
    Oncotarget; 2016 Jan 19; 7(3):3084-97. PubMed ID: 26625211
    [Abstract] [Full Text] [Related]

  • 17. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling.
    Wang N, Song L, Xu Y, Zhang L, Wu Y, Guo J, Ji W, Li L, Zhao J, Zhang X, Zhan L.
    EBioMedicine; 2019 Sep 19; 47():65-77. PubMed ID: 31495720
    [Abstract] [Full Text] [Related]

  • 18. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression.
    Sui C, Meng F, Li Y, Jiang Y.
    J Transl Med; 2015 Apr 28; 13():132. PubMed ID: 25927928
    [Abstract] [Full Text] [Related]

  • 19. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
    Rao C, Miao X, Zhao G, Zhang C, Shen H, Dong C, Yang M.
    Biomed Pharmacother; 2019 Jun 28; 114():108662. PubMed ID: 30999114
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
    Li JH, Luo N, Zhong MZ, Xiao ZQ, Wang JX, Yao XY, Peng Y, Cao J.
    Tumour Biol; 2016 Feb 28; 37(2):2387-94. PubMed ID: 26376998
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.